Last week's agreement between Ligand Pharmaceuticals Inc. and Organon Pharmaceuticals USA Inc. to end their co-promotion deal for the oral morphine product Avinza renewed chatter related to Ligand's takeover prospects - and talk already was active about other potential buyouts, as the pharma industry moves ever more aggressively to beef up its pipelines and capabilities. (BioWorld Financial Watch) Read More
